317 related articles for article (PubMed ID: 28864633)
21. Characterization of the radiolabeled metabolite of tau PET tracer
Harada R; Furumoto S; Tago T; Furukawa K; Ishiki A; Tomita N; Iwata R; Tashiro M; Arai H; Yanai K; Kudo Y; Okamura N
Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2211-2218. PubMed ID: 27430946
[TBL] [Abstract][Full Text] [Related]
22. A comparison of five partial volume correction methods for Tau and Amyloid PET imaging with [
Shidahara M; Thomas BA; Okamura N; Ibaraki M; Matsubara K; Oyama S; Ishikawa Y; Watanuki S; Iwata R; Furumoto S; Tashiro M; Yanai K; Gonda K; Watabe H
Ann Nucl Med; 2017 Aug; 31(7):563-569. PubMed ID: 28639126
[TBL] [Abstract][Full Text] [Related]
23. Early brainstem [18F]THK5351 uptake is linked to cortical hyperexcitability in healthy aging.
Van Egroo M; Chylinski D; Narbutas J; Besson G; Muto V; Schmidt C; Marzoli D; Cardone P; Vandeleene N; Grignard M; Luxen A; Salmon E; Lambert C; Bastin C; Collette F; Phillips C; Maquet P; Bahri MA; Balteau E; Vandewalle G
JCI Insight; 2021 Jan; 6(2):. PubMed ID: 33290274
[TBL] [Abstract][Full Text] [Related]
24. Novel 18F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease.
Okamura N; Furumoto S; Harada R; Tago T; Yoshikawa T; Fodero-Tavoletti M; Mulligan RS; Villemagne VL; Akatsu H; Yamamoto T; Arai H; Iwata R; Yanai K; Kudo Y
J Nucl Med; 2013 Aug; 54(8):1420-7. PubMed ID: 23857514
[TBL] [Abstract][Full Text] [Related]
25.
Chun MY; Lee J; Jeong JH; Roh JH; Oh SJ; Oh M; Oh JS; Kim JS; Moon SH; Woo SY; Kim YJ; Choe YS; Kim HJ; Na DL; Jang H; Seo SW
Yonsei Med J; 2022 Mar; 63(3):259-264. PubMed ID: 35184428
[TBL] [Abstract][Full Text] [Related]
26. Quantitative evaluation of tau PET tracers
Chen J; Li Y; Pirraglia E; Okamura N; Rusinek H; de Leon MJ;
Eur J Nucl Med Mol Imaging; 2018 Jul; 45(9):1596-1604. PubMed ID: 29704038
[TBL] [Abstract][Full Text] [Related]
27. Longitudinal changes in
Ezura M; Kikuchi A; Ishiki A; Okamura N; Hasegawa T; Harada R; Watanuki S; Funaki Y; Hiraoka K; Baba T; Sugeno N; Oshima R; Yoshida S; Kobayashi J; Kobayashi M; Tano O; Nakashima I; Mugikura S; Iwata R; Taki Y; Furukawa K; Arai H; Furumoto S; Tashiro M; Yanai K; Kudo Y; Takeda A; Aoki M
Eur J Neurol; 2019 Sep; 26(9):1205-1211. PubMed ID: 30980575
[TBL] [Abstract][Full Text] [Related]
28. THK5351 and flortaucipir PET with pathological correlation in a Creutzfeldt-Jakob disease patient: a case report.
Kim HJ; Cho H; Park S; Jang H; Ryu YH; Choi JY; Moon SH; Oh SJ; Oh M; Na DL; Lyoo CH; Kim EJ; Seeley WW; Kim JS; Choi KC; Seo SW
BMC Neurol; 2019 Aug; 19(1):211. PubMed ID: 31464590
[TBL] [Abstract][Full Text] [Related]
29. Clinical Evaluation of 18F-PI-2620 as a Potent PET Radiotracer Imaging Tau Protein in Alzheimer Disease and Other Neurodegenerative Diseases Compared With 18F-THK-5351.
Oh M; Oh SJ; Lee SJ; Oh JS; Roh JH; Chung SJ; Lee JH; Lee CS; Kim JS
Clin Nucl Med; 2020 Nov; 45(11):841-847. PubMed ID: 32910050
[TBL] [Abstract][Full Text] [Related]
30. [Imaging of neuropathology by PET tracers].
Harada R
Nihon Yakurigaku Zasshi; 2022; 157(6):453-457. PubMed ID: 36328560
[TBL] [Abstract][Full Text] [Related]
31. Imaging in-vivo tau pathology in Alzheimer's disease with THK5317 PET in a multimodal paradigm.
Chiotis K; Saint-Aubert L; Savitcheva I; Jelic V; Andersen P; Jonasson M; Eriksson J; Lubberink M; Almkvist O; Wall A; Antoni G; Nordberg A
Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1686-99. PubMed ID: 26996778
[TBL] [Abstract][Full Text] [Related]
32. Monoamine Oxidase B Binding of 18F-THK5351 to Visualize Glioblastoma and Associated Gliosis: An Autopsy-Confirmed Case.
Tago T; Toyohara J; Sengoku R; Murayama S; Ishii K
Clin Nucl Med; 2019 Jun; 44(6):507-509. PubMed ID: 30985435
[TBL] [Abstract][Full Text] [Related]
33. Investigation of the quantitative accuracy of low-dose amyloid and tau PET imaging.
Nai YH; Watanuki S; Tashiro M; Okamura N; Watabe H
Radiol Phys Technol; 2018 Dec; 11(4):451-459. PubMed ID: 30328073
[TBL] [Abstract][Full Text] [Related]
34. Synthesis and evaluation of 2-pyrrolopyridinylquinoline derivatives as selective tau PET tracers for the diagnosis of Alzheimer's disease.
Lerdsirisuk P; Harada R; Hayakawa Y; Shimizu Y; Ishikawa Y; Iwata R; Kudo Y; Okamura N; Furumoto S
Nucl Med Biol; 2021 Feb; 93():11-18. PubMed ID: 33221641
[TBL] [Abstract][Full Text] [Related]
35. Head-to-Head Comparison of the Two MAO-B Radioligands, 18F-THK5351 and 11C-L-Deprenyl, to Visualize Astrogliosis in Patients With Neurological Disorders.
Ishibashi K; Kameyama M; Miura Y; Toyohara J; Ishii K
Clin Nucl Med; 2021 Jan; 46(1):e31-e33. PubMed ID: 32657879
[TBL] [Abstract][Full Text] [Related]
36. Preclinical Evaluation of
Honer M; Gobbi L; Knust H; Kuwabara H; Muri D; Koerner M; Valentine H; Dannals RF; Wong DF; Borroni E
J Nucl Med; 2018 Apr; 59(4):675-681. PubMed ID: 28970331
[TBL] [Abstract][Full Text] [Related]
37. Astrocytosis precedes amyloid plaque deposition in Alzheimer APPswe transgenic mouse brain: a correlative positron emission tomography and in vitro imaging study.
Rodriguez-Vieitez E; Ni R; Gulyás B; Tóth M; Häggkvist J; Halldin C; Voytenko L; Marutle A; Nordberg A
Eur J Nucl Med Mol Imaging; 2015 Jun; 42(7):1119-32. PubMed ID: 25893384
[TBL] [Abstract][Full Text] [Related]
38. MicroPET Imaging Assessment of Brain Tau and Amyloid Deposition in 6 × Tg Alzheimer's Disease Model Mice.
Kang S; Kim J; Lee SY; Okamura N; Chang KA
Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628296
[TBL] [Abstract][Full Text] [Related]
39. Test-Retest Reproducibility for the Tau PET Imaging Agent Flortaucipir F 18.
Devous MD; Joshi AD; Navitsky M; Southekal S; Pontecorvo MJ; Shen H; Lu M; Shankle WR; Seibyl JP; Marek K; Mintun MA
J Nucl Med; 2018 Jun; 59(6):937-943. PubMed ID: 29284675
[TBL] [Abstract][Full Text] [Related]
40. Correlation of In Vivo [18F]Flortaucipir With Postmortem Alzheimer Disease Tau Pathology.
Smith R; Wibom M; Pawlik D; Englund E; Hansson O
JAMA Neurol; 2019 Mar; 76(3):310-317. PubMed ID: 30508025
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
